This startup operates a contract research organization specializing in custom aptamer functional studies for diagnostics and therapeutic applications, utilizing an automated platform for aptamer identification and characterization. Their services support the development of aptamer-based imaging probes and biosensors, addressing the need for precise tools in biomedical research and clinical diagnostics.
Funding
$400K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional antibody-based methods for target recognition in diagnostics, therapeutics, and analytical applications face limitations in terms of stability, production costs, and the ability to target non-immunogenic molecules. The development of rapid and cost-effective assays for detecting a wide range of targets, from small molecules to complex biological entities, remains a challenge.
Solution
Novaptech is a contract research organization (CRO) specializing in the development of custom aptamers, which are single-stranded DNA or RNA oligonucleotides engineered to bind specific molecular targets with high affinity and specificity. Utilizing the SELEX (Systematic Evolution of Ligands by EXponential enrichment) process, Novaptech identifies and optimizes aptamers for various applications, including diagnostics, therapeutics, and analytical assays. The company's services encompass aptamer selection against diverse targets, characterization of binding properties, and optimization for improved stability and functionality. Novaptech also offers expertise in developing aptamer-based assays, including rapid tests and biosensors, providing clients with versatile tools for target detection and analysis.
Target Audience
Novaptech serves biotechnology, pharmaceutical, agri-food, and environmental companies, as well as academic laboratories and R&D departments seeking custom aptamer solutions for diagnostics, therapeutics, and analytical applications.
Features
- Custom aptamer selection against a wide range of targets, including small molecules, peptides, proteins, viruses, bacteria, and eukaryotic cells
- SELEX process employing proprietary libraries and selection strategies to identify high-affinity aptamers
- Selection of DNA, RNA, and chemically-modified RNA aptamers
- Aptamer characterization using Surface Plasmon Resonance, Bio-Layer Interferometry, and fluorescence emission to assess binding properties and specificity
- Aptamer optimization through truncation, chemical modification, and conjugation to enhance stability, functionality, and detection capabilities
- Development of aptamer-based assays, including ELISA-like assays, biosensors, lateral flow assays, and rapid tests
- NOVAswitch technology for structure-switching aptamers, enabling multiplexed detection of small molecules
- Partnership with Eurogentec for large-scale aptamer synthesis and chemical modification under GMP conditions
- R&D program focused on innovative aptamer selection methodologies and assay designs